219 related articles for article (PubMed ID: 31931281)
1. xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells.
Bekeschus S; Eisenmann S; Sagwal SK; Bodnar Y; Moritz J; Poschkamp B; Stoffels I; Emmert S; Madesh M; Weltmann KD; von Woedtke T; Gandhirajan RK
Redox Biol; 2020 Feb; 30():101423. PubMed ID: 31931281
[TBL] [Abstract][Full Text] [Related]
2. Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism.
Luo Y; Xiang W; Liu Z; Yao L; Tang L; Tan W; Ye P; Deng J; Xiao J
Free Radic Biol Med; 2022 May; 184():53-65. PubMed ID: 35367340
[TBL] [Abstract][Full Text] [Related]
3. ROS Mediate xCT-Dependent Cell Death in Human Breast Cancer Cells under Glucose Deprivation.
Chen MC; Hsu LL; Wang SF; Hsu CY; Lee HC; Tseng LM
Cells; 2020 Jul; 9(7):. PubMed ID: 32630312
[TBL] [Abstract][Full Text] [Related]
4. The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate.
Koppula P; Zhang Y; Shi J; Li W; Gan B
J Biol Chem; 2017 Aug; 292(34):14240-14249. PubMed ID: 28630042
[TBL] [Abstract][Full Text] [Related]
5. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Huang Y; Dai Z; Barbacioru C; Sadée W
Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098
[TBL] [Abstract][Full Text] [Related]
6. Expression of xCT and activity of system xc(-) are regulated by NRF2 in human breast cancer cells in response to oxidative stress.
Habib E; Linher-Melville K; Lin HX; Singh G
Redox Biol; 2015 Aug; 5():33-42. PubMed ID: 25827424
[TBL] [Abstract][Full Text] [Related]
7. Stress-induced inhibition of nonsense-mediated RNA decay regulates intracellular cystine transport and intracellular glutathione through regulation of the cystine/glutamate exchanger SLC7A11.
Martin L; Gardner LB
Oncogene; 2015 Aug; 34(32):4211-8. PubMed ID: 25399695
[TBL] [Abstract][Full Text] [Related]
8. Aspirin plus sorafenib potentiates cisplatin cytotoxicity in resistant head and neck cancer cells through xCT inhibition.
Roh JL; Kim EH; Jang H; Shin D
Free Radic Biol Med; 2017 Mar; 104():1-9. PubMed ID: 28057599
[TBL] [Abstract][Full Text] [Related]
9. xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling.
Liu J; Xia X; Huang P
Mol Ther; 2020 Nov; 28(11):2358-2366. PubMed ID: 32931751
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
11. xCT knockdown in human breast cancer cells delays onset of cancer-induced bone pain.
Ungard RG; Linher-Melville K; Nashed MG; Sharma M; Wen J; Singh G
Mol Pain; 2019; 15():1744806918822185. PubMed ID: 30799686
[TBL] [Abstract][Full Text] [Related]
12. Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy.
Koppula P; Zhuang L; Gan B
Protein Cell; 2021 Aug; 12(8):599-620. PubMed ID: 33000412
[TBL] [Abstract][Full Text] [Related]
13. CD44v-dependent upregulation of xCT is involved in the acquisition of cisplatin-resistance in human lung cancer A549 cells.
Horibe S; Kawauchi S; Tanahashi T; Sasaki N; Mizuno S; Rikitake Y
Biochem Biophys Res Commun; 2018 Dec; 507(1-4):426-432. PubMed ID: 30448176
[TBL] [Abstract][Full Text] [Related]
14. Rotavirus-induced lncRNA SLC7A11-AS1 promotes ferroptosis by targeting cystine/glutamate antiporter xCT (SLC7A11) to facilitate virus infection.
Banerjee S; Sarkar R; Mukherjee A; Mitra S; Gope A; Chawla-Sarkar M
Virus Res; 2024 Jan; 339():199261. PubMed ID: 37923170
[TBL] [Abstract][Full Text] [Related]
15. Variant isoforms of CD44 involves acquisition of chemoresistance to cisplatin and has potential as a novel indicator for identifying a cisplatin-resistant population in urothelial cancer.
Hagiwara M; Kikuchi E; Tanaka N; Kosaka T; Mikami S; Saya H; Oya M
BMC Cancer; 2018 Jan; 18(1):113. PubMed ID: 29385995
[TBL] [Abstract][Full Text] [Related]
16. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
[TBL] [Abstract][Full Text] [Related]
17. Redox-dependent AMPK inactivation disrupts metabolic adaptation to glucose starvation in xCT-overexpressing cancer cells.
Lee Y; Itahana Y; Ong CC; Itahana K
J Cell Sci; 2022 Aug; 135(15):. PubMed ID: 35775474
[TBL] [Abstract][Full Text] [Related]
18. The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility.
Shin CS; Mishra P; Watrous JD; Carelli V; D'Aurelio M; Jain M; Chan DC
Nat Commun; 2017 Apr; 8():15074. PubMed ID: 28429737
[TBL] [Abstract][Full Text] [Related]
19. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
20. High expression of cystine-glutamate antiporter xCT (SLC7A11) is an independent biomarker for epileptic seizures at diagnosis in glioma.
Sørensen MF; Heimisdóttir SB; Sørensen MD; Mellegaard CS; Wohlleben H; Kristensen BW; Beier CP
J Neurooncol; 2018 May; 138(1):49-53. PubMed ID: 29404978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
